Company Description
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers.
It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 25, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Iain Dukes |
Contact Details
Address: 12 Penns Trail Newtown, Pennsylvania 18940 United States | |
| Phone | 267 759 3680 |
| Website | trawspharma.com |
Stock Details
| Ticker Symbol | TRAW |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130598 |
| CUSIP Number | 68232V884 |
| ISIN Number | US68232V8845 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Chief Executive Officer, Secretary and Director |
| Dr. Victor Moyo M.D. | Chief Medical Officer of Oncology |
| Charles Parker | Chief Financial Officer |
| Dr. Nikolay Savchuk Ph.D. | Chief Operating Officer and Director |
| Dr. Robert R. Redfield M.D. | Chief Medical Officer |
| Dr. Charles David Pauza Ph.D. | Chief Scientific Officer of Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 28, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 8-K | Current Report |
| Oct 17, 2025 | 8-K | Current Report |
| Oct 14, 2025 | 8-K | Current Report |
| Oct 8, 2025 | ARS | Filing |
| Oct 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |